SemaThera develops novel semaphorin 3A (SEMA 3A) inhibitors for the prevention and reversal of diabetic macular edema (DME).
SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema. Its levels are significantly elevated in the vitreous of patients with DME as well as in several other vascular diseases of the retina.
Importantly, SEMA 3A levels rise in the early stages of DME, while VEGF levels are still as low as in non-diabetic controls.
Inhibiting SEMA 3A with SemaThera’s biological traps has shown robust pre-clinical efficacy in preventing retinal vascular leakage, inflammation, apoptosis and pathological cytoskeleton remodelling..